The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).
 
Angel Alsina
Honoraria - Eisai; Eisai; Eisai; Eisai
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai
Speakers' Bureau - Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis
 
Masatoshi Kudo
Honoraria - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Arndt Vogel
Honoraria - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Delcath Systems; Delcath Systems; Delcath Systems; Delcath Systems; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Baxalta; Baxalta; Baxalta; Baxalta; Bayer; Bayer; Bayer; Bayer; Delcath Systems; Delcath Systems; Delcath Systems; Delcath Systems; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche
Research Funding - Novartis; Novartis; Novartis; Novartis
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Ipsen; Ipsen; Ipsen; Ipsen; Roche; Roche; Roche; Roche
 
Ann-Lii Cheng
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Lilly; Lilly; Lilly; Lilly
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; BeiGene; BeiGene; BeiGene; BeiGene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; CSR Pharma; CSR Pharma; CSR Pharma; CSR Pharma; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; IQVIA; IQVIA; IQVIA; IQVIA; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
 
Won Young Tak
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Bukwang Pharmaceutical; Bukwang Pharmaceutical; Bukwang Pharmaceutical; Bukwang Pharmaceutical; Eisai; Eisai; Eisai; Eisai; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Yuhan; Yuhan; Yuhan; Yuhan
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Bukwang Pharmaceutical; Bukwang Pharmaceutical; Bukwang Pharmaceutical; Bukwang Pharmaceutical; Eisai; Eisai; Eisai; Eisai; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Yuhan; Yuhan; Yuhan; Yuhan
Speakers' Bureau - Abbvie; Abbvie; Abbvie; Abbvie; Bayer; Bayer; Bayer; Bayer; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Yuhan; Yuhan; Yuhan; Yuhan
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Consulting or Advisory Role - Karus Therapeutics (Inst); Karus Therapeutics (Inst); Karus Therapeutics (Inst); Karus Therapeutics (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Medivir (Inst); Medivir (Inst); Medivir (Inst); Medivir (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre
Other Relationship - Genmab; Genmab; Genmab; Genmab
 
Carlos Lopéz Lopéz
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - Amgen; Amgen; Amgen; Amgen; AstraZeneca Spain; AstraZeneca Spain; AstraZeneca Spain; AstraZeneca Spain; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
 
Bruno Daniele
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; MSD; MSD; MSD; MSD; Sanofi; Sanofi; Sanofi; Sanofi
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Sanofi; Sanofi; Sanofi; Sanofi
 
Jean-Frédéric Blanc
Honoraria - Baxalta/Shire; Baxalta/Shire; Baxalta/Shire; Baxalta/Shire; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Consulting or Advisory Role - Baxalta/Shire; Baxalta/Shire; Baxalta/Shire; Baxalta/Shire; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis; Novartis; Novartis; Novartis; Onxeo; Onxeo; Onxeo; Onxeo
Travel, Accommodations, Expenses - Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma
 
Min Ren
Employment - Eisai; Eisai; Eisai; Eisai
 
Rae Lynn Baldwin
Employment - Eisai; Eisai; Eisai; Eisai
Stock and Other Ownership Interests - Biogen; Biogen; Biogen; Biogen
 
Namiki Izumi
Honoraria - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai
 
Shukui Qin
No Relationships to Disclose
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis; Novartis; Novartis; Novartis